Article 4: The implementation of rapid microbiological methods
0
SHARES
Posted: 19 August 2010 |
This is the fourth in a series of articles on rapid microbiological methods that will appear in European Pharmaceutical Review during 2010. Believe it or not, today’s regulatory authorities encourage the use of rapid microbiological methods (RMMs), and when applicable, they have put policies in place that provide guidance on how to get a RMM approved. Because there are different regulatory perspectives on RMM implementation, a company should understand what each regulatory body expects with regard to validation, submission and implementation strategies. In my last article, I discussed a number of RMM implementation perspectives from the U.S. Food and Drug Administration (FDA). In this article, I will focus on the European Medicines Agency (EMA) and their expectations on the introduction of new RMM technologies.
This is the fourth in a series of articles on rapid microbiological methods that will appear in European Pharmaceutical Review during 2010. Believe it or not, today’s regulatory authorities encourage the use of rapid microbiological methods (RMMs), and when applicable, they have put policies in place that provide guidance on how to get a RMM approved. Because there are different regulatory perspectives on RMM implementation, a company should understand what each regulatory body expects with regard to validation, submission and implementation strategies. In my last article, I discussed a number of RMM implementation perspectives from the U.S. Food and Drug Administration (FDA). In this article, I will focus on the European Medicines Agency (EMA) and their expectations on the introduction of new RMM technologies.
Like their U.S. counterparts, European regulators have been supporting the industry to validate and implement RMM and PAT technologies. For example, Paul Hargreaves (Technical Manager, U.K. Medicines and Healthcare Products Regulatory Agency; MHRA) has viewed the implementation of alternative microbiology methods as a positive step in improving the quality of medicines and patient safety, and has actively encouraged the industry to implement these technologies for many years1. Additionally, in order to support PAT activities in the European Union (EU), an EMA PAT team was created that includes the Quality Working Party and the ad hoc GMP/GDP Inspectors Working Group. The aim of this team is to review the implications of PAT and to ensure that the European regulatory framework and the authorities are prepared for and adequately equipped to conduct thorough and effective evaluations of PAT-based submissions. The EMA PAT team believes that the current regulatory framework in Europe is open to the implementation of PAT in marketing authorisation applications, especially when the application includes Quality by Design (QbD) strategies. In addition, the ICH Guideline on Pharmaceutical Development (ICH Q8)2, now adopted by EU, also includes provisions on the use of PAT applications.
Unfortunately, only a small number of RMM regulatory applications have been submitted in the EU, and regulators have expressed their disappointment in the industry’s hesitancy in embracing the change from conventional methods to alternative methods. One reason for this apparent lack of willingness to move microbiology technology forward has been the industry’s perception that the current European regulatory framework actually hinders, instead of encourages, the implementation of RMMs. For example, many end-users consider the European regulatory environment for sub missions as being more complicated and not as straightforward as the procedures they have used for RMM approvals in the U.S. Although individual member states have approved RMMs for routine use, many of the tools provided by the FDA do not exist within the EMA. Next, there is no equivalent to the comparability protocol in Europe, and companies have had no formal process for submitting a RMM validation strategy for review and approval prior to the initiation of the actual testing plan. For some companies, it has taken almost 18 months for their RMM validation dossier to be reviewed and commented on by numerous member states, thereby extending the time for RMM implementation. Furthermore, for those RMMs intended to replace existing microbiology methods that have been incorporated into marketing authorisations, the filing of multiple type variations has been required for each product and facility, instead of being managed under a single comparability protocol, which is the strategy that many companies have used in the U.S. This process is both time-consuming and costly. Therefore, in order to encourage the industry to implement RMMs within the EU, it is critical that the regulatory environment change in order to relieve the regulatory burdens associated with RMM validation strategies, and for the EMA to move towards a simpler, clearer and more flexible framework with regard to type variations. Fortunately, significant changes have very recently occurred which paved the way for a friendlier and simpler strategy for RMM implementation within Europe.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
On 1 January 2010, new revisions to variations regulation 1234/2008 went into effect and apply to variations to a marketing authorisation granted in a Mutual Recognition / Decentralised Procedure and to Community or Centralised authorisations3. The new variations regulation introduces a number of features such as annual reporting for minor type IA changes, type IB by default and implementing new procedures such as ‘work-sharing’ and ‘grouping of variations’ aiming to reduce the workload for both competent authorities and applicants. With the review of the variations regulations (new variations regulation 1234/2008) and the release of Directive 2009/53/EC for changing the legal basis of the variations regulation, the way towards the last major change has been cleared: all authorised medicinal products, including those authorised at the purely national level, will now be subject to the same criteria for the evaluation, approval and administrative handling of changes, regardless of the procedure under which those medicines have been initially authorised. These changes were previously outlined in the 2007 public consultation paper, ‘Better Regulation of Pharmaceuticals: Towards a simpler, clearer and more flexible framework on variations’. More importantly, the changes will have a significant impact on the way RMMs will be implemented in Europe and this was the focus of a full-day meeting hosted by the Parenteral Drug Association (PDA) on 21 September 2009 in Frankfurt, Germany. An overview of the major discussion points during this meeting is provided below.
PDA forum on implementing RMMs in Europe
European regulators agreed to dedicate a discussion forum to practical questions about the implementation of RMMs in Europe, as the process appeared to not be well understood by the pharma – ceutical industry. Specifically, it was perceived that:
Implementing RMMs is a complex regulatory scenario
It can become very costly, if variations to marketing authorisations are involved
The time horizon to get approval for implementation might be unpredictable, especially if the product or products concerned possess heterogeneous marketing authorisations
Discussions with regulators on scientific and practical questions seem not to be endorsed before a formal application is submitted, leaving the risk of missing aspects crucial to the authorities and related delays to the applicant
Three European regulators served as panellists during this meeting; they included Paul Hargreaves (MHRA inspector), Gustavo Marco (MHRA reviewer) and Riccardo Luigetti (EMA and PAT team member). Below are some of the topics that were discussed.
Type variations
The revisions for type variations will provide clearer, simpler and more flexible options, reduced regulatory administrative burden, adaptation to ICH concepts and harmonisation across the national authorities. One of the most important changes relating to RMMs is that it will be possible to group variations under the same marketing authorisation such that they can all be assessed at the same time. Furthermore, it will be possible to combine the same variations or group of variations from different marketing authorisations and have all of these assessed at the same time under what is called a work sharing process (or a common assessment). This could be the case for a single RMM technology being used for multiple products. Finally, it is under discussion that there may be a possibility of having pre-authorised, post approval change management plans and protocols. Hopefully, we will hear more about these additional opportunities later in the year.
Scientific advice
There will be new opportunities for scientific dialog with regulators through the EMA Scientific Advice (SA) procedure. The SA procedure is used for scientific issues concerning quality, non-clinical and clinical aspects relating to the proposed future development of the medicinal product and focuses on general strategies. The SA procedure is also used during the early stages of product development but is not intended to offer a pre-review of data in support of a marketing authorisation application. The SA procedure applies to the entire EU; however, individual national authorities may require additional discussions in addition to the advice received under this procedure. The SA is not legally binding and can be contradicted once the application is under official review; however, you will receive an official document from the EMA SA working party.
Validation expectations
Ph. Eur. chapter 5.1.64 is the guidance that should be used when validating RMMs in Europe. The regulators are ready to evaluate the data from validation studies; however, there have been few RMM applications submitted and Riccardo Luigetti agrees that the existing process is moving slowly. He also stated that there is no prejudice or preclusion of introducing alternative microbiological methods. In fact, the EMA Quality Working Party (QWP) and the ad hoc GMP inspector’s group published guidance on using RMMs for pharmaceutical water including WFI5. The introduction of such methods might require specific review to ensure that the appropriate validation steps (in Ph. Eur. 5.1.6) have been followed and that the water continues to meet the Ph. Eur. specifications. Since it is expected that the water will continue to meet Ph. Eur. specification, if tested, no change to dossier requirements would be involved and therefore no regulatory impact on individual products would normally be anticipated. This would, however, depend on the level of detail in the original dossiers concerned.
The primary validation should include a characterisation of the principle of detection using a panel of challenge microorganisms. A risk-benefit analysis should also be included which would address the limitations of both the RMM and the compendial method. The PQ demonstrates that the method has been validated for its intended use and this is performed using actual product. Additionally, the method must be comparable to test results characterised in a model system as evaluated by the vendor. Finally, the RMM must be shown to be at least equivalent to the compendial method. Furthermore, the specific characteristics of the microbial methods should be described, such as the use of specific equipment or method variability. It is also very important that the validation includes metabolically and physically injured organisms, starved cells, environmental monitoring isolates and spores, when applicable. Cells grown under ideal and stressed conditions can also be used to determine any differences between the RMM and the compendial methods.
Summary
This article provides a brief overview of EMA regulatory perspectives when validating and implementing RMMs. Because RMM qualification strategies can be influenced by the RMM technology, method or application, and/or the product or test sample, it is important to discuss your proposed plans with the relevant regulatory authority and/or local inspectorate in advance of finalising your testing approach. For a more in-depth review of the EMA’s perspectives and validation expectations, you are encouraged to visit the Regulatory Information Page at http://rapidmicromethods.com, a new website dedicated to the advancement and implementation of rapid microbiological methods.
References
1. Hargreaves, P. (2007) The Inspectorate Viewpoint on Rapid Microbiology Methods. PDA Rapid Microbiology Methods Conference, Verona, Italy. 5-6 February
2. ICH. Q8: Pharmaceutical Development (2009) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonized Tripartite Guideline, Q8 (R2), Current Step 4 version
3. European Medicines Agency. Regulatory and Procedural Guidance. http://www. ema.europa.eu/docs/en_GB/document_libra ry/Regulatory_and_procedural_guideline/20 09/10/WC500003981.pdf
4. European Pharmacopoeia (2010) 6.8. Informational chapter 5.1.6. Alternative methods for control of microbiological quality. European Directorate for the Quality of Medicines (EDQM), Strasbourg, France
5. European Medicines Agency (2005) Inspections – Quality Working Party – Questions & Answers. Water – Microbiological Control of Water http://www.ema. europa.eu/ema/index.jsp?curl=pages/regulat ion/q_and_a/q_and_a_detail_000072.jsp& mid=WC0b01ac058002c2b0&murl=menus/ regulations/regulations.jsp&jsenabled=- true#section11
About the Author
Dr. Michael J. Miller
Dr. Michael J. Miller is an inter – nationally recognised microbiologist and subject matter expert in pharmaceutical microbiology and the design, validation and implementation of rapid microbiological methods. He is currently the President of Microbiology Consultants, LLC (http://microbiologyconsultants.com). In this role, he is responsible for providing scientific, quality, regulatory and business solutions for the pharmaceutical industry and suppliers of new microbiology technologies. Over the past 21 years, Dr. Miller has held numerous R&D, manufacturing, quality, consulting and business development leadership roles at Johnson & Johnson, Eli Lilly and Company, Bausch & Lomb, and Pharmaceutical Systems, Inc.
Dr. Miller has authored over 100 technical publications and presentations in the areas of rapid microbiological methods, PAT, ophthalmics, disinfection and sterilisation, is the editor of PDA’s Encyclopaedia of Rapid Microbiological Methods, and is the owner of http://rapidmicromethods.com, a new website dedicated to the advancement of RMMs. He currently serves on a number of PDA’s program and publication committees and advisory boards, and is co-chairing the revision of PDA Technical Report #33: Evaluation, Validation and Implementation of New Microbiological Testing Methods.
Dr. Miller holds a Ph.D. in Microbiology and Biochemistry from Georgia State University (GSU), a B.A. in Anthropology and Sociology from Hobart College, and is currently an adjunct professor at GSU. He was appointed the John Henry Hobart Fellow in Residence for Ethics and Social Justice, awarded PDA’s Distinguished Service Award and was named Microbiologist of the Year by the Institute of Validation Technology (IVT).
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.